United Therapeutics (UTHR) Tops Q2 EPS by 82c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to United Therapeutics (UTHR) Tops Q2 EPS by 82c

United Therapeutics Corporation Reports Second Quarter 2018 Financial Results

August 1, 2018 6:00 AM EDT

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 1, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2018.

"Our second quarter net revenues totaled $444 million and we are treating a larger number of patients, compared to the prior year, suffering from pulmonary arterial hypertension with our prostacyclin product franchise, which consists of Orenitram, Remodulin, and Tyvaso," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We also continued to invest in our innovative product pipeline, which includes... More